The role of cardiovascular assessment in low risk thyroid neoplasm patients: results from a tertiary care center experience

Stefano Gay, Martina Comina, Marsida Teliti, Eleonora Monti, Manuela Albertelli, Italo Porto, Gian Marco Rosa, Livio Bottiglieri, Massimo Giusti, Diego Ferone


Background: After surgery, clinical approach to thyroid neoplasms often involves TSH suppression. An increased cardiovascular (CV) risk due to thyroid hormones excess has already been proved. Aim of the study was to evaluate the role of CV assessment in preventing new events and optimizing the follow-up of these patients.

Methods: After thyroidectomy for low risk thyroid neoplasms, a cohort of 108 women was retrospectively evaluated. A first examination (V1) at the end of primary treatments and a second one (V2) five years later were considered.  Clinical and echocardiographic evaluations were performed in each examination. Patients were divided into 3 subclasses depending on TSH-suppression degree in the study period. New cardiovascular events, initiation of  new therapies and cardiovascular deaths were recorded.  

Results: The incidence of CV events was 7,4%. Patients age (p=0.032), previous CV events (p=0.001), use of lipid-lowering (p=0.002) and antiplatelet (p=0.027) drugs and diabetes mellitus (p=0,049) were associated with total CV events;  interventricular septum thickness, BMI and tryglicerides value with ischaemic events (sensitivity 66,6%, 100%, 80%; specificity 91,1%, 55,1%, 77,2%, respectively; p<0.001); TSH-suppression class with arrhythmic events (p=0.035); an increased left ventricular mass index ratio between V2 and V1 with both total (p=0.001) and ischaemic (p=0.002) CV events.

Conclusions: After primary treatments for thyroid neoplasm, a complete CV assessment is advisable in defining TSH-suppression target. Ultrasound parameters appear useful in evaluating CV risk both at baseline and during the follow-up. A periodic revaluation of those parameters may allow the prevention or early diagnosis of new events and complications.


Cardiovascular risk, Thyroid cancer, TSH-suppression

Full Text:



Haugen BR, Alexander EK, Bible KC, Doherty GM, Mandel SJ, Nikiforov YE, et al. 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid. 2016;26(1):1-133.

Biondi B, Cooper DS. Thyroid hormone suppression therapy. Endocrinol Metab Clin North Am. 2019;48(1):227-37.

Hovens GC, Stokkel MP, Kievit J, Corssmit EP, Pereira AM, Romijn JA et al. Associations of serum thyrotropin concentrations with recurrence and death in differentiated thyroid cancer. J Clin Endocrinol Metab. 2007;92(7):2610-5.

Park S, Kim WG, Han M, Jeon MJ, Kwon H, Kim M et al. Thyrotropin Suppressive Therapy for Low-Risk Small Thyroid Cancer: A Propensity Score-Matched Cohort Study. Thyroid. 2017;27(9):1164-70.

Stroup AM, Harrell CJ, Herget KA. Long-term survival in young women: hazards and competing risks after thyroid cancer. J Cancer Epidemiol. 2012;2012:641372.

Pajamäki N, Metso S, Hakala T, Ebeling T, Huhtala H, Ryödi E et al. Long-term cardiovascular morbidity and mortality in patients treated for differentiated thyroid cancer. Clin Endocrinol (Oxf). 2018;88(2):303-10.

Reddy V, Taha W, Kundumadam S, Khan M. Atrial fibrillation and hyperthyroidism: A literature review. Indian Heart J. 2017;69(4):545-50.

Gammage MD, Parle JV, Holder RL, Roberts LM, Hobbs FD, Wilson S et al. Association between serum free thyroxine concentration and atrial fibrillation. Arch Intern Med. 2007;167(9):928-34.

Gullu S, Altuntas F, Dincer I, Erol C, Kamel N. Effects of TSH-suppressive therapy on cardiac morphology and function: beneficial effects of the addition of beta-blockade on diastolic dysfunction. Eur J Endocrinol. 2004;150(5):655-61.

Bano A, Chaker L, de Maat MPM, Atiq F, Kavousi M, Franco OH. Thyroid Function and Cardiovascular Disease: The Mediating Role of Coagulation Factors. J Clin Endocrinol Metab. 2019;104(8):3203-12.

Elbers LPB, Fliers E, Cannegieter SC. The influence of thyroid function on the coagulation system and its clinical consequences J Thromb Haemost. 2018;16(4):634-45.

Bano A, Chaker L, Mattace-Raso FUS, van der Lugt A, Ikram MA, Franco OH, et al. Thyroid Function and the Risk of Atherosclerotic Cardiovascular Morbidity and Mortality: The Rotterdam Study. Circ Res. 2017;121(12):1392-1400.

Amin MB, Greene FL, Edge SB, Compton CC, Gershenwald JE, Brookland RK et al. The Eighth Edition AJCC Cancer Staging Manual: Continuing to build a bridge from a population-based to a more "personalized" approach to cancer staging. CA Cancer J Clin. 2017;67(2):93-9.

Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972;18(6):499-502.

Toulis KA, Viola D, Gkoutos G, Keerthy D, Boelaert K, Nirantharakumar K. Risk of incident circulatory disease in patients treated for differentiated thyroid carcinoma with no history of cardiovascular disease. Clin Endocrinol (Oxf). 2019;91(2):323-30.

Izkhakov E, Meyerovitch J, Barchana M, Shacham Y, Stern N, Keinan-BokerL. Long-term cardiovascular and cerebrovascular morbidity in Israeli thyroid cancer survivors. Endocr Connect. 2019;pii:EC-19-0038.

Park J, Blackburn BE, Ganz PA, Rowe K, Snyder J, Wan Y et al. Risk Factors for Cardiovascular Disease Among Thyroid Cancer Survivors: Findings From the Utah Cancer Survivors Study. J Clin Endocrinol Metab. 2018;103(7):2468-77.

Levy D, Garrison RJ, Savage DD, Kannel WB, Castelli WP. Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. N Engl J Med. 1990;322(22):1561-6.

Bombelli M, Facchetti R, Carugo S, Madotto F, Arenare F, Quarti-Trevano F et al. Left ventricular hypertrophy increases cardiovascular risk independently of in-office and out-of-office blood pressure values. J Hypertens. 2009; 27(12):2458-64.

Huang BT, Peng Y, Liu W, Zhang C, Huang FY, Wang PJ et al. Increased interventricular septum wall thickness predicts all-cause death in patients with coronary artery disease. Intern Med J. 2015; 45(3):275-83.

von Jeinsen B, Short MI, Larson MG, Xanthakis V, McManus DD, Benjamin EJ et al. Prognostic Significance of Echocardiographic Measures of Cardiac Remodeling. J Am Soc Echocardiogr. 2019; S0894-7317(19):30912-5.

Wang R, Yang L, Jin S, Han X, Liu B. Thyroid stimulating hormone suppression time on cardiac function of patients with differentiated thyroid carcinoma. Cancer Cell Int. 2018;18:189.

Shargorodsky M, Serov S, Gavish D, Leibovitz E, Harpaz D, Zimlichman R. Long-term thyrotropin-suppressive therapy with levothyroxine impairs small and large artery elasticity and increases left ventricular mass in patients with thyroid carcinoma. Thyroid. 2006;16(4):381-6.

Parker WA, Edafe O, Balasubramanian SP. Long-term treatment-related morbidity in differentiated thyroid cancer: a systematic review of the literature. Pragmat Obs Res. 2017;8:57-67.

Taillard V, Sardinoux M, Oudot C, Fesler P, Rugale C, Raingeard I, et al. Early detection of isolated left ventricular diastolic dysfunction in high-risk differentiated thyroid carcinoma patients on TSH-suppressive therapy. Clin Endocrinol (Oxf). 2011; 75(5):709-14.

Smit JW, Eustatia-Rutten CF, Corssmit EP, Pereira AM, Frölich M, Bleeker GB et al. Reversible diastolic dysfunction after long-term exogenous subclinical hyperthyroidism: a randomized, placebo-controlled study. J Clin Endocrinol Metab. 2005; 90(11):6041-7.

Tadic M, Ilic S, Ivanovic B, Celic V. Left atrial phasic function and mechanics in women with subclinical hypothyroidism: the effects of levothyroxine therapy. Echocardiography. 2014; 31(10):1221-9.

Giusti M, Mortara L, Degrandi R, Cecoli F, Mussap M, Rodriguez G et al. Metabolic and cardiovascular risk in patients with a history of differentiated thyroid carcinoma: A case-controlled cohort study. Thyroid Res. 2008;1(1):2.

Duntas LH, Brenta G. The effect of thyroid disorders on lipid levels and metabolism. Med Clin North Am. 2012;96(2):269-81.

Lee YK, Lee H, Han S, Jung H, Shin DY, Nam KH. Association between Thyroid-Stimulating Hormone Level after Total Thyroidectomy and Hypercholesterolemia in Female Patients with Differentiated Thyroid Cancer: A Retrospective Study. J Clin Med. 2019;8(8):E1106.

Heemstra KA, Smit JW, Eustatia-Rutten CF, Heijboer AC, Frölich M, Romijn JA, et al. Glucose tolerance and lipid profile in long term exogenous subclinical hyperthyroidism and the effects of restoration of euthyroidism, a randomised controlled trial. Clin Endocrinol (Oxf). 2006;65(6):737-44.

Kwon H, Cho JH, Lee DY, Park SE, Park CY, Lee WY et al. Association between thyroid hormone levels, body composition and insulin resistance in euthyroid subjects with normal thyroid ultrasound: The Kangbuk Samsung Health Study. Clin Endocrinol (Oxf). 2018;89(5):649-55.

De Melo TG, Souza AL, Ficher E, Fernandes AM, Montali Da Assumpção LV, Monte Alegre S, et al. Reduced insulin sensitivity in differentiated thyroid cancer patients with suppressed TSH. Endocr Res. 2018;43(2):73-9.

Mullur R, Liu YY, Brent GA. Thyroid hormone regulation of metabolism. Physiol Rev. 2014;94(2):355-82.

Izkhakov E, Vaisman N, Barnes S, Barchana M, Stern N, Keinan-Boker L. Body Composition, Resting Energy Expenditure, and Metabolic Changes in Women Diagnosed with Differentiated Thyroid Carcinoma. Thyroid. 2019;29(8):1044-51.

Ojomo KA, Schneider DF, Reiher AE, Lai N, Schaefer S, Chen H et al. Using body mass index to predict optimal thyroid dosing after thyroidectomy. J Am Coll Surg. 2013;216(3):454-60.

Ghaznavi SA, Ganly I, Shaha AR, English C, Wills J, Tuttle RM. Using the American Thyroid Association Risk-Stratification System to Refine and Individualize the American Joint Committee on Cancer Eighth Edition Disease-Specific Survival Estimates in Differentiated Thyroid Cancer. Thyroid. 2018;28(10):1293-300.